ChemicalBook > CAS DataBase List > Adriamycin

Adriamycin

Product Name:
Adriamycin
CAS No.
23214-92-8
Chemical Name:
Adriamycin
CBNumber:
CB1170865
Molecular Formula:
C27H29NO11
Formula Weight:
543.52
MOL File:
23214-92-8.mol
More
Less

Adriamycin Property

Melting point:
205°C
Boiling point:
617.77°C (rough estimate)
Density 
1.3783 (rough estimate)
refractive index 
1.6400 (estimate)
storage temp. 
-20°C
pka
pKa 8.2 (Uncertain)
Water Solubility 
Soluble
CAS DataBase Reference
23214-92-8
EPA Substance Registry System
Doxorubicin (23214-92-8)
More
Less

Safety

Hazardous Substances Data
23214-92-8(Hazardous Substances Data)
More
Less

Adriamycin Chemical Properties,Usage,Production

Antitumor antibiotics

Adriamycin is a kind of anthracycline antitumor antibiotics produced by Streptomyces peucetius sub sp caesius, belonging to cell cycle non-specific drug (CCNSA). Cells of S and M phases are most sensitive to it. Its hydrochloride appears as orange needle crystal. The melting point is 204 ~ 205 ℃. It is easily soluble in water, ethanol and methanol. The aqueous solution is stable and stays constant at 5 ° C for 1 month but is not stable at higher temperatures or in acidic or alkaline solutions. The acidic aqueous solution is orange, neutral orange-red, alkaline (pH> 9) purple-blue. It is insoluble in acetone, benzene, petroleum ether, ether and chloroform. It is an antitumor antibiotic isolated from the actinomycetes culture. The mechanism of action is similar to daunorubicin, which has a broader anti-tumor spectrum and a higher therapeutic index. It is clinically applied for the treatment of acute and chronic lymphocytic leukemia and solid tumor leukemia, lymphoma, breast cancer, ovarian cancer, soft tissue sarcoma, osteogenic sarcoma, rhabdomyosarcoma, Ewing's sarcoma, nephroblastoma, neuroblastoma, gastric cancer, pancreatic cancer, liver cancer, prostate cancer, head and neck squamous cell carcinoma, testicular cancer, lung cancer, bladder cancer, medullary thyroid carcinoma and sarcoma. This product can cause myelosuppression, gastrointestinal reactions and cardiac toxicity. 4'-Epirubicin (4'-epi-adriamycin) is the reverse configuration of the C4 hydroxyl in the glycosyl group of Adriamycin. Its anti-tumor effect is similar to that of Adriamycin, but its cardiotoxicity is low. 4'-deoxyadriamycin (4'-deoxyadriamycin) has a different antitumor spectrum of animal tumors with doxorubicin with lower damage to the heart compared to doxorubicin.

Pharmacological effects

This product belongs to anthracycline antineoplastic drugs, having similar structure to daunorubicin with the only difference being an H-hydroxy substitution in the side chain 14 carbon atoms. It has both fat-soluble anthracene ring ligand and water-soluble daunosamine. It also has acidic phenolic hydroxyl and basic amino group, thus having a strong anticancer pharmacological activity. Adriamycin is obtained from the culture Str. Pe-ucetius var. Caesius. Owing to the quinone-hydroquinone structure on the anthracene ring ligand in the molecule, it has the ability of accepting electrons and providing neutrons, to be inserted between adjacent base pairs of DNA, generating active free radicals, unwinding and breaking DNA double helix. It can further inhibit the activity of the nucleic acid template, interfering with the transcription process to prevent mRNA synthesis. In addition it may cause cell membrane rupture, exhibiting cytotoxicity, belonging to a cell cycle non-specific drug. This product has the function of forming superoxide radicals, and has a special role in the destruction of cell membrane structure and function. It is effective in the targeting all stages of the cells, but being of highest efficient in the treatment of the early S phase cells, followed by M, with the G1 phase being most insensitive to it. It can delay the G1, S and G2 phase. However, the maximum cytotoxicity occurs in S phase and is more sensitive to early S and M phase cells. Adriamycin can cause chromosome aberrations in cells and increase the exchange rate of chromatids.
This product has poor oral absorption, and should be administrated by only intravenous injection. Its plasma protein binding rate is low. It can rapidly disappear from the blood after injection, being widely distributed in the heart, stomach, lung, liver and spleen organizations, but no penetrating through the blood-brain barrier. Plasma attenuation curve is divided into three phases with half-life being 12 minutes, 3.3 hours and 30 hours, respectively. It is mainly subject to liver metabolism with the main metabolite being doxorubicin alcohol, having a considerable anti-cancer activity. Approximately 40% to 50% of the dose is excreted by bile after 7 days of administration, of which 50% is prototype and 23% is active metabolite. 5% to 10% of urine excreted. Upon liver and renal insufficiency, doxorubicin stay in the body for longer with the clear curve exhibiting heterogeneous phases and its three-phase T1 / 2 were 0.5 hours, 3 hours and 40 to 50 hours, respectively. It is clinical mainly for the treatment of acute or chronic leukemia, Hodgkin and non-Hodgkin's lymphoma and malignant lymphoma. Daunorubicin resistant tumors are still sensitive to doxorubicin. It also has certain efficacy in the treatment of Ewing's tumor, osteosarcoma, soft tissue tumor, lung cancer, choriocarcinoma, breast cancer, bladder cancer, thyroid cancer and soft tissue tumors. It combination with cytarabine, vincristine and fluorouracil can increase its efficacy. Tumor cells are resistant to doxorubicin. Drug-resistant cells, compared to the sensitive cells, have lower permeability of the cell membrane, decreased cellular uptake doxorubicin reduction, and can actively discharge doxorubicin. Daunorubicin resistant cells may also be cross-resistant to doxorubicin.

Adverse reactions

A dose of more than 500mg / m2, 25% to 30% can possibly lead to ECG abnormalities, arrhythmia and decreased cardiac function. There are few cases of congestive heart failure, myocardial degeneration, local necrosis, and even death. 60% to 80% may have myelosuppression, manifested as leukopenia, thrombocytopenia and anemia with reaching minimum in 7 to 10 days and recovering at the first 4 weeks. In addition, there may be nausea and vomiting, mouth ulcers. Similar to daunorubicin, side effects of doxorubicin include cardiotoxicity, bone marrow suppression, nausea, vomiting and stomatitis as well as hair loss. Early signs of cardiac toxicity exhibit temporary ECG changes with the majority undergoing self-remission. Late (chronic) cardiotoxicity, also known as delayed cardiomyopathy that is dose related, is irreversible serious myocardial disease with severe cases being lethal. Therefore, heart disease and hypertension patients should use with caution. There are phlebitis, skin pigmentation and liver damage. Cardiotoxicity patients can administrate vitamin E, vitamin C, coenzyme Q10, N-acetyl cysteine and selenium preparations. Heart failure patients may be given digitalis preparations and diuretics.

Medicine interactions

  • Cross-resistant to daunorubicin, vincristine and actinomycin D.
  • Synergistic effect with cyclophosphamide, fluorouracil, methotrexate, chlorelimide, cisplatin and nitrosoureas.
  • Used with caution during live virus vaccination.
  • Combination with azathioprine or mercaptopurine can increase doxorubicin liver toxicity.

Chemical Properties

Adriamycin is an orange to red cake-like or needle-like crystalline solid.

Uses

Doxorubicin (adriamycin) is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumour agent for the treatment of a wide range of cancers. Doxorubicin also exhibits anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

Uses

Doxorubicin USP (Adriamycin) is used to traet soft-tissue and osteogenic sarcomas; Hodgkin’s disease; non-Hodgkin’s lymphomas; acute leukemia; cancer of thyroid, breast, lung, genitourinary (GU) tract; Wilm’s tumor; neuroblastoma.

Indications

Doxorubicin binds tightly to DNA by its ability to intercalate between base pairs and therefore is preferentially concentrated in nuclear structures. Intercalation results in steric hindrance, hence production of single-strand breaks in DNA and inhibition of DNA synthesis and DNA-dependent RNA synthesis. The enzyme topoisomerase II is thought to be involved in the generation of DNA strand breaks by the anthracyclines. Cells in S-phase are most sensitive to doxorubicin, although cytotoxicity also occurs in other phases of the cell cycle.

brand name

Adriblastina (Farmitalia, Societa Farmaceutici Italia, Italy).

Mechanism of action

Doxorubicin is not absorbed orally, and because of its ability to cause tissue necrosis must not be injected intramuscularly or subcutaneously. Distribution studies indicate rapid uptake in all tissues except the CNS. Extensive tissue binding, primarily intranuclear, accounts for the prolonged elimination half-life.The drug is extensively metabolized in the liver to hydroxylated and conjugated metabolites and to aglycones that are primarily excreted in the bile.

Clinical Use

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin’s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing’s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non–oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis.

Side effects

The most important toxicities caused by doxorubicin involve the heart and bone marrow.Acutely, doxorubicin may cause transient cardiac arrhythmias and depression of myocardial function. Doxorubicin may cause radiation recall reactions, with flare-ups of dermatitis, stomatitis, or esophagitis that had been produced previously by radiation therapy. Less severe toxicities include phlebitis and sclerosis of veins used for injection, hyperpigmentation of nail beds and skin creases, and conjunctivitis. Because of its intense red color, doxorubicin will impart a reddish color to the urine for 1 or 2 days after administration.

Safety Profile

Confirmed carcinogen with experimental carcinogenic, neoplastigenic, and tumorigenic data. Poison by intraperitoneal, subcutaneous, parenteral, and intravenous routes. Human systemic effects by intravenous route: cardiac myopathy including infarction, nausea or vomiting, and effects on the hair. An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits very toxic fumes of NO, and HCl

Potential Exposure

An antibiotic product from streptomyces, used as anticancer drug

Carcinogenicity

Adriamycin is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity from studies in experimental animals.

Shipping

UN2811 Toxic solids, organic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials, Technical Name Required.

Incompatibilities

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, epoxides

Waste Disposal

It is inappropriate and possibly dangerous to the environment to dispose of expired or waste pharmaceuticals by flushing them down the toilet or discarding them to the trash. Household quantities of expired or waste pharmaceuticals may be mixed with wet cat litter or coffee grounds, double-bagged in plastic, discard in trash. Larger quantities shall carefully take into consideration applicable DEA, EPA, and FDA regulations. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.

Adriamycin Preparation Products And Raw materials Raw materials

Raw materials

DCM

Preparation Products

Less

Adriamycin Suppliers

Global(157)Suppliers
Hubei kangmingde Pharmaceutical Chemical Co., Ltd
Tel:
027-89771658-
Fax:
027-89771658
Email:
hbtcky@163.com
Country:
China
ProdList:
4990
Advantage:
56
Beijing Ouhe Technology Co., Ltd
Tel:
010-82967028-
Fax:
+86-10-82967029
Email:
2355560935@qq.com
Country:
China
ProdList:
12365
Advantage:
60
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel:
13817811078,021-50426030
Fax:
86-021-50426522,50426273
Email:
sales@jingyan-chemical.com
Country:
China
ProdList:
10009
Advantage:
60
Jia Xing Isenchem Co.,Ltd
Tel:
0573-85280080-
Fax:
0573-85285100
Email:
isenchem@163.com;
Country:
China
ProdList:
9674
Advantage:
66
LGM Pharma
Tel:
1-(800)-881-8210
Fax:
615-250-9817
Email:
inquiries@lgmpharma.com
Country:
United States
ProdList:
1938
Advantage:
70
Nanjing Chemlin Chemical Co., Ltd
Tel:
025-83697070
Fax:
+86-25-83453306
Email:
info@chemlin.com.cn
Country:
China
ProdList:
19991
Advantage:
64
Chemsky (shanghai) International Co.,Ltd
Tel:
021-50135380
Email:
shchemsky@sina.com
Country:
China
ProdList:
15425
Advantage:
60
China Langchem Inc.
Tel:
021-58956006- ;021-58950017-
Fax:
021-58956100
Email:
sales@langchem.com;sales@langchem.com
Country:
China
ProdList:
1338
Advantage:
57
Shanghai Sunway Pharmaceutical Technology Co., Ltd
Tel:
021-51613915- ;021-51613915-822
Fax:
021 51613951
Email:
latika.cui@3wpharm.com;vivian.zhu@3wpharm.com
Country:
China
ProdList:
9879
Advantage:
57

23214-92-8, AdriamycinRelated Search:

N-(3-pyridylmethyl)adriamycin Detorubicin N-trifluoroacetyladriamycin N,N-bis(3-pyridylmethyl)adriamycin N,N-dimethyldoxorubicin [14C]ADRIAMYCIN HYDROCHLORIDE 14-salicyloyldaunorubicin N-trifluoroacetyladriamycin-14-O-hemiadipate Nemorubicin N-benzyladriamycin Adriamycin Epirubicin Glycine 3-Aminophenol Methoxy 6-Aminocaproic acid ALTRENOGEST Centchroman
  • Doxorubicin hydrohloride
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • DOXORUBICIN
  • 10-((3-amino-2,3,6-trideoxy-alpha-l-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • (1s,3s)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranoside
  • ADRIAMYCIN
  • Adriamycin Adriamycin
  • (8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione
  • 14-Hydroxydaunomycin
  • adiblastine (hydrochloride salt)
  • adriablastine (hydrochloride salt)
  • adriablatina (hydrochloride salt)
  • Adriacin (hydrochloride salt)
  • Adriamycin PFS
  • Adriamycin PFS (hydrochloride salt)
  • Adriamycin RDF
  • Adriamycin RDF (hydrochloride salt)
  • Adriblastin
  • Adriblastina (hydrochloride salt)
  • adriblatina (hydrochloride salt)
  • Doxorubicin hydrochloride (hydrochloride salt)
  • Farmablastina (hydrochloride salt)
  • Hydroxydaunomycin hydrochloride (hydrochloride salt)
  • Hydroxydaunorubicin hydrochloride (hydrochloride salt)
  • Rubex
  • Rubex (hydrochloride salt)
  • 5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-
  • 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
  • Doxil
  • NSC 123127
  • ADRIAMYCINSEMIQUINONE
  • (85-cis)-10-[(3-amino-2,3,6-trideoxy-alpha-l-lyxohexapyranosyl)oxy]-7,8,9,10- t
  • adriamycine
  • etrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
  • DOXOPINHYDROCHLORIDE
  • (85-Cis)-10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-methoxy-5,12-Naphthacenedione
  • (8S)-10-((4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
  • (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
  • NCI-C-01514
  • 10-((3-AMino-2,3,6-trideoxy-α-L-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-Methoxy-5,12-naphthacenedione
  • Doxorubicin base
  • (8S,10S)-10-{[(2R,4S,5S,6S)-4-aMino-5-hydroxy-6-Methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-Methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
  • Biotransdox
  • Evacet
  • HydroxydaunoMycin
  • PK 2
  • Rubidox
  • Doxorubicin Free Base
  • Doxorubincine
  • AdriaMycin, 14-HydroxydaunoMycin, FI 106, K 1039, KW 125, NSC 123127
  • PROK2
  • Prokineticin-2 human
  • Protein Bv8 homolog
  • ADRIAMYCIN, PHARMA
  • 23214-92-8
  • C27H29NO11
Antitumor antibiotics Pharmacological effects Adverse reactions Medicine interactions